We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-16.43%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$791B
AUM Growth
-$200B
Cap. Flow
-$11.4B
Cap. Flow %
-1.44%
Top 10 Hldgs %
26.42%
Holding
3,063
New
88
Increased
1,490
Reduced
1,207
Closed
101

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$3.46B
2
UNH icon
UnitedHealth
UNH
+$2.79B
3
CRM icon
Salesforce
CRM
+$2.38B
4
SHW icon
Sherwin-Williams
SHW
+$1.41B
5
PM icon
Philip Morris
PM
+$1.34B

Sector Composition

Rank Sector Weight
1 Technology 26.68%
2 Healthcare 19.49%
3 Consumer Discretionary 13.07%
4 Financials 11.17%
5 Communication Services 8.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RSI icon
2676
Rush Street Interactive
RSI
$2.86B
$140K ﹤0.01%
29,878
-3,698
-11% -$22K
VHC icon
2677
VirnetX Holding Corp
VHC
$67.6M
$138K ﹤0.01%
5,885
-322
-5% -$8.97K
TAL icon
2678
TAL Education Group
TAL
$6.43B
$137K ﹤0.01%
28,200
GOGL
2679
DELISTED
Golden Ocean Group
GOGL
$136K ﹤0.01%
+11,715
New +$157K
NABL icon
2680
N-able
NABL
$623M
$135K ﹤0.01%
14,955
-1,488
-9% -$14.6K
PXLW icon
2681
Pixelworks
PXLW
$43.7M
$135K ﹤0.01%
5,875
MYOV
2682
DELISTED
Myovant Sciences Ltd.
MYOV
$135K ﹤0.01%
10,900
KVHI icon
2683
KVH Industries
KVHI
$146M
$134K ﹤0.01%
+15,400
New +$125K
NNBR icon
2684
NN Inc
NNBR
$297M
$134K ﹤0.01%
52,920
-4,053
-7% -$11.2K
ADVWW
2685
DELISTED
Advantage Solutions Warrant
ADVWW
$133K ﹤0.01%
579,414
-562,590
-49% -$330K
NKLA
2686
DELISTED
Nikola Corporation Common Stock
NKLA
$133K ﹤0.01%
929
+252
+37% +$51.5K
GEVO icon
2687
Gevo
GEVO
$398M
$132K ﹤0.01%
56,279
+2,349
+4% +$8.59K
AMRN
2688
Amarin Corp
AMRN
$299M
$131K ﹤0.01%
4,387
ORGO icon
2689
Organogenesis Holdings
ORGO
$230M
$131K ﹤0.01%
26,821
+300
+1% +$1.85K
ACCD
2690
DELISTED
Accolade Inc
ACCD
$131K ﹤0.01%
17,673
-784,783
-98% -$6.86M
SPRU icon
2691
Spruce Power Holding Corp
SPRU
$36M
$130K ﹤0.01%
14,088
-869
-6% -$10K
SPWH icon
2692
Sportsman's Warehouse
SPWH
$46.4M
$130K ﹤0.01%
13,541
+300
+2% +$2.96K
QTTB icon
2693
Q32 Bio
QTTB
$465M
$130K ﹤0.01%
3,667
-202
-5% -$6.9K
ME
2694
DELISTED
23andMe Holding Co
ME
$130K ﹤0.01%
2,620
+1,590
+154% +$92.1K
AUPH icon
2695
Aurinia Pharmaceuticals
AUPH
$2.01B
$129K ﹤0.01%
+12,799
New +$143K
PBYI icon
2696
Puma Biotechnology
PBYI
$461M
$129K ﹤0.01%
45,400
-2,868
-6% -$7.13K
CTAQ
2697
DELISTED
Carney Technology Acquisition Corp. II Class A Common Stock
CTAQ
$129K ﹤0.01%
13,038
CHMI
2698
Cherry Hill Mortgage Investment Corp
CHMI
$107M
$128K ﹤0.01%
19,976
+946
+5% +$6.52K
MITT
2699
TPG Mortgage Investment Trust
MITT
$213M
$128K ﹤0.01%
19,000
TFFP
2700
DELISTED
TFF Pharmaceuticals, Inc. Common Stock
TFFP
$128K ﹤0.01%
908

Similar funds

T. Rowe Price Associates's Q2 2022 Portfolio in Review

As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
  • T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
  • T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
  • T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
  • T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
  • T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
  • T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.